1. 代表中華民國癌症醫學會(TOS，Taiwan Oncology Society)出席訂定國際（全亞洲）「癌症治療指引」（Pan-Asian adapted ESMO consensus guidelines），目前共發表6篇大腸癌(Ann Oncol. 2018; 29(1): 44、Ann Oncol 2021; 32(12):1496、ESMO Open 2023;8(3):101558.)、胃癌(Ann Oncol. 2019;30(1):19)、食道癌(Ann Oncol. 2019 ; 30(1):34)、全癌(跨癌別)(agnostic) MSI/NTRK (Ann Oncol 2020;31(7):861)。 2. 積極參與“國際多中心大規模臨床試驗”，推動消化道腫瘤抗癌新藥獲準。 以胃癌、大腸癌為例： ◎ATTRACTION-2 phase III trial: nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens. (Lancet 2017;390:2461-2471), leading to TFDA approval. ◎KEYNOTE-061 phase III trial: pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer. (Lancet 2018;392:123-133). ◎CONCUR phase III trial: regorafenib monotherapy in asian patients with previously treated metastatic colorectal cancer (Lancet Oncol 2015;16:619-29). ◎KEYNOTE-177 phase III trial: pembrolizumab in microsatellite-instability–high advanced colorectal cancer (N Engl J Med. 2020;383:2207-2218). 3. 與日本癌症醫院東病院(National Cancer Center East)合作進行大腸癌患者術後循環腫瘤DNA(ctDNA)之大規模前瞻性IIT研究。 ◎GALAXY study：研究預計招募5,000名患者，目前已招募超過3,000名患者。初步報告已陸續發表在2021 annual meeting of European Society for Medical Oncology (ESMO), the 2022 American Society of Clinical Oncology (ASCO) GI cancers symposium, the 2023 annual meeting of Japanese Society of Medical Oncology (JSMO), the 2023 annual meeting of ASCO, and the 2024 annual meeting of ASCO. 4. 近五年獲獎： (1) 2022，臺大醫院「研究卓越團隊獎」 — 消化道癌臨床試驗團隊 (2) 2023，徐千田癌症研究傑出獎 (3) 2023，元大文教基金會「醫師科學家獎」（葉坤輝教授/梁逸歆醫師 － 師生同時獲獎）

台灣是C型肝炎高盛行區，我們發現台灣存在有C型肝炎鄉鎮，盛行率高達30%-67%，推估全國約有554,361人感染慢性C型肝炎，因此C型肝炎在台灣之防治刻不容緩。吾等團隊長期致力於C型肝炎相關疾病研究，特別是病毒分子生物診斷學、分子流行病學、致病機轉及臨床病程、與肝外疾病關聯、免疫遺傳學、治療療程與療效提昇與影響療效因子、長期預後等研究，近來更致力於建立「C肝微根除」模式。余等之系列性研究從「促進慢性C型肝炎治療療效研究」、「C型肝炎個別化治療之轉譯醫學研究」、「C型肝炎資源導向治療之精準醫學研究」到之成果已被歐洲肝臟學會，亞太肝臟學會，台灣肝臟學會及行政院衛生福利部健保署所引用作為治療準則，包括： 1)以病毒基因學及病毒動力學成功規劃慢性C型肝炎長效型干擾素合併雷巴威林個人化治療之最適療程。 2)以宿主基因體多型態結合病毒學發展而出的『資源導向C型肝炎精準治療』。 3)藉由藥物經濟學及外展篩檢、在地治療團隊模式、結合新一代C型肝炎治療藥物，成功發展出『C肝微根除行動計畫』策略。 吾等之系列C型肝炎研究之創新與成果，特別是「應用病毒學與藥物基因體學於慢性C型肝炎抗病毒藥物個別化治療之轉譯醫學研究及資源導向治療之C型肝炎精準醫學研究」有極大之突破，最新結合新一代C型肝炎治療藥物，更成功發展出『C肝微根除』策略，受到國際學術界肯定，亦對全球醫藥科技發展、中華民國國民健康和國家社會均有實質貢獻，協助國家及世界衛生組織達成根除C型肝炎的終極目標。

1. National Leader, Taiwan Clinical Trial Consortium for Liver Diseases -Successful conduction of several investigator-initiated trials -Efficient facilitation of many international and domestic multi-center clinical trials sponsored by pharmaceutical companies 2. Principal investigator, A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects with Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection Achievements: -Confirm that HBV co-infection does not impact HCV SVR after DAA therapy -Prove that ledipasvir/sofosbuvir is effective for the treatment of HCV genotype 2 -Clarify risk and profile of HBV reactivation during and after DAA therapy Clinical impacts: -Lead to approval of ledipasvir/sofosbuvir for the treatment of HCV genotype 2 in many countries including Taiwan. The speed toward eradication of HCV infection in Taiwan national project before 2025 is facilitated. -The sponsor had very good profit after this new indication for HCV genotype 2, which is prevalent in Asia-Pacific region. -The safety of patients with HBV/HCV coinfection is improved due to the clarification of the risk of HBV reactivation. 3. National leader: The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis Achievements: Integrate Taiwan sites and facilitate recruitment of suitable subjects 4. President, 2022 APASL Single Topic Conference on HCC (Asia-Pacific international conference) 5. Associate editor, Liver International, Journal of the Formosan Medical Association, Journal of Microbiology, Immunolo and Infection 6 World's Top 2% Scientists, Stanford University statistics 2020

1. Great contribution to DAA drug development for HCV 2. Early phase drug development for HBV treatment 3. Early phase drug development for HCC treatment 4. Early phase drug development for NASH treatment

1. Great contribution to the treatment of Helicobacter pylori and gastric cancer prevention 2. Involved in the Taipei global consensus for gastric cancer prevention (Gut 2020;69:2093-2112) 3. Chair of the Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM) 4. Global leading PI (Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial, clarithromycin, amoxicillin, metronidazole, lansoprazole) 5. Global leading PI (Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial, bismuth (KCB), clarithromycin, amoxicillin, metronidazole, lansoprazole)

劉志銘醫師(Jyh-Ming Liou)長期致力於幽門螺旋桿菌治療與胃癌預防相關的研究，建立幽門桿菌抗藥性分析的實驗平台與臨床試驗多中心合作平台，進行多項幽門桿菌治療創新研發之臨床試驗，開發幽門螺旋桿菌族群與個人最佳療法，並探討除菌治療對於腸道菌叢抗藥性及腸道外疾病與健康之長期影響，成果刊登於｢THE LANCET｣(刺胳針2013,2016及子期刊2017,2019)、胃腸學 (Gastroenterology 2018)、胃腸病 (GUT 2010,2015,2016,2020) 等國際頂尖期刊，這些研究不僅引領幽門螺旋桿菌的治療方向，並因此改變了幽門螺旋桿菌的治療準則。基於這些重要的成果，劉醫師籌畫及舉辦胃癌預防的台北全球共識會議，以實證醫學的方法，研擬出26點專家共識，將有助於為全球胃幽門螺旋桿菌治療及胃癌防治政策提供更深入且完整的依據，成果以台北國際共識為標題，刊登於2020年12月的國際頂尖醫學期刊 GUT，同時也獲選為該期雜誌的封面

消化道篩檢預防臨床試驗